All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
On March 29, 2020, the United States Food and Drug Administration (FDA) granted orphan drug designation to SEL120 for the treatment of patients with acute myeloid leukemia.1-2
SEL120 is an oral cyclin-dependent kinase 8 and 19 (CDK8/19) inhibitor. CDK8 and CDK19 play key roles in proliferation and viability of cancer cell lines. SEL120 binding CDK8/19 prevents activation of CDK8/19-mediated oncogenic signaling pathways and inhibits proliferation of CDK8/19-overexpressing tumor cells.3 SEL120 has shown strong proof of concept in preclinical studies and has received strategic support from the Leukemia & Lymphoma Society through its therapy acceleration program.
Adverse events in acute myeloid leukemia (AML) treatment
AML treatment often includes intense chemotherapy regimes, at induction, through consolidation and possibly following allogeneic stem cell transplantation for treatment of relapse.
Acute myeloid leukemia with t(6;9): a retrospective analysis of patient outcomes
In the subset of patients with t(6;9)(p22,q34), whose outcomes are rarely reported, this study has shown high CR rates after intensive induction therapy,.
Subscribe to get the best content related to AML delivered to your inbox